[go: up one dir, main page]

ZA200203702B - Adenosine receptor antagonists and methods of making and using the same. - Google Patents

Adenosine receptor antagonists and methods of making and using the same.

Info

Publication number
ZA200203702B
ZA200203702B ZA200203702A ZA200203702A ZA200203702B ZA 200203702 B ZA200203702 B ZA 200203702B ZA 200203702 A ZA200203702 A ZA 200203702A ZA 200203702 A ZA200203702 A ZA 200203702A ZA 200203702 B ZA200203702 B ZA 200203702B
Authority
ZA
South Africa
Prior art keywords
making
methods
same
receptor antagonists
adenosine receptor
Prior art date
Application number
ZA200203702A
Other languages
English (en)
Inventor
James E Dowling
Gnanasambandam Kumaravel
Carol Ensinger
Russell C Peter
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of ZA200203702B publication Critical patent/ZA200203702B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200203702A 1999-11-12 2002-05-09 Adenosine receptor antagonists and methods of making and using the same. ZA200203702B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
ZA200203702B true ZA200203702B (en) 2003-10-29

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203702A ZA200203702B (en) 1999-11-12 2002-05-09 Adenosine receptor antagonists and methods of making and using the same.

Country Status (33)

Country Link
US (4) US6605600B1 (et)
EP (2) EP1230241B1 (et)
JP (1) JP2003513976A (et)
KR (1) KR100845488B1 (et)
CN (1) CN1187354C (et)
AT (1) ATE353328T1 (et)
AU (1) AU784528B2 (et)
BG (1) BG106693A (et)
BR (1) BR0015540A (et)
CA (1) CA2390590C (et)
CY (1) CY1106560T1 (et)
CZ (1) CZ20021615A3 (et)
DE (1) DE60033310T2 (et)
DK (1) DK1230241T3 (et)
EA (1) EA010260B1 (et)
EE (1) EE200200248A (et)
ES (1) ES2281367T3 (et)
GE (1) GEP20043267B (et)
HK (1) HK1049153B (et)
HU (1) HUP0203371A3 (et)
IL (1) IL149486A0 (et)
IS (1) IS6380A (et)
MX (1) MXPA02004795A (et)
NO (1) NO20022237L (et)
NZ (2) NZ519427A (et)
PL (1) PL198156B1 (et)
PT (1) PT1230241E (et)
SK (1) SK6622002A3 (et)
TR (1) TR200301062T2 (et)
UA (1) UA77937C2 (et)
WO (1) WO2001034604A2 (et)
YU (1) YU33702A (et)
ZA (1) ZA200203702B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
PT1230243E (pt) * 1999-11-12 2009-06-12 Biogen Idec Inc Policicloalquilpurinas como antagonistas dos receptores da adenosina
HUP0203371A3 (en) * 1999-11-12 2005-02-28 Biogen Idec Ma Inc Cambridge Adenosine receptor antagonists and methods of making and using the same
RS107404A (sr) * 2002-06-12 2007-02-05 Biogen Idec Ma Inc., Metod lečenja ishemične povrede izazvane poremećajem perfuzije upotrebom antagonista adenozinskog receptora
US20040106797A1 (en) * 2002-07-19 2004-06-03 Pascal Druzgala Novel xanthines having adenosine A1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
JP3984281B2 (ja) * 2003-04-14 2007-10-03 ファイザー・プロダクツ・インク ３−アザビシクロ〔３，２，１〕オクタン誘導体
WO2004096228A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
JP4859666B2 (ja) * 2003-06-06 2012-01-25 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
EP2001479A2 (en) * 2006-04-06 2008-12-17 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
DK2018380T3 (da) 2006-05-19 2012-01-23 Abbott Lab CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE3843117A1 (de) 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
EP0423805B1 (en) 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Condensed purine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
EP0541120B1 (en) 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
EP0556778A3 (en) 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (et) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (fr) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
AU7675598A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Hepatic edema remedy
WO1998057644A1 (en) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
AU4396899A (en) 1998-07-02 2000-01-24 Kyowa Hakko Kogyo Co. Ltd. Remedies for diabetes
PT1230243E (pt) * 1999-11-12 2009-06-12 Biogen Idec Inc Policicloalquilpurinas como antagonistas dos receptores da adenosina
HUP0203371A3 (en) * 1999-11-12 2005-02-28 Biogen Idec Ma Inc Cambridge Adenosine receptor antagonists and methods of making and using the same

Also Published As

Publication number Publication date
WO2001034604A2 (en) 2001-05-17
DK1230241T3 (da) 2007-06-04
CZ20021615A3 (cs) 2002-08-14
AU2042101A (en) 2001-06-06
SK6622002A3 (en) 2003-02-04
UA77937C2 (en) 2007-02-15
NZ519427A (en) 2003-08-29
AU784528B2 (en) 2006-04-27
MXPA02004795A (es) 2005-07-01
CA2390590A1 (en) 2001-05-17
EA010260B1 (ru) 2008-06-30
EP1775297A3 (en) 2008-12-03
PL356044A1 (en) 2004-06-14
CY1106560T1 (el) 2012-01-25
HUP0203371A3 (en) 2005-02-28
DE60033310T2 (de) 2007-11-22
JP2003513976A (ja) 2003-04-15
PL198156B1 (pl) 2008-05-30
WO2001034604A3 (en) 2002-01-10
BG106693A (bg) 2003-01-31
YU33702A (sh) 2005-03-15
EE200200248A (et) 2003-06-16
KR20020049043A (ko) 2002-06-24
EP1230241B1 (en) 2007-02-07
NO20022237D0 (no) 2002-05-10
TR200301062T2 (tr) 2003-09-22
US6605600B1 (en) 2003-08-12
PT1230241E (pt) 2007-05-31
IL149486A0 (en) 2002-11-10
ATE353328T1 (de) 2007-02-15
CN1399636A (zh) 2003-02-26
US20050222179A1 (en) 2005-10-06
EP1230241A2 (en) 2002-08-14
CA2390590C (en) 2010-03-16
US20030225038A1 (en) 2003-12-04
IS6380A (is) 2002-05-10
NO20022237L (no) 2002-07-12
HK1049153B (en) 2007-09-28
HK1049153A1 (en) 2003-05-02
DE60033310D1 (de) 2007-03-22
EP1775297A2 (en) 2007-04-18
KR100845488B1 (ko) 2008-07-10
ES2281367T3 (es) 2007-10-01
US20080004293A1 (en) 2008-01-03
NZ527918A (en) 2005-05-27
BR0015540A (pt) 2002-07-23
EA200200562A1 (ru) 2002-10-31
GEP20043267B (en) 2004-06-25
HUP0203371A2 (hu) 2003-02-28
CN1187354C (zh) 2005-02-02

Similar Documents

Publication Publication Date Title
ZA200203701B (en) Polycycloalkylpurines as adenosine receptor antagonists.
ZA200203702B (en) Adenosine receptor antagonists and methods of making and using the same.
IL146871A0 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
NZ329627A (en) 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
AU1213892A (en) Novel 8-substituted purines as selective adenosine receptor agents
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
GB9815618D0 (en) Treatment of dyskinesia
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
ZA200504565B (en) 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system